Skip to main content
CLYM logo

CLYM · Climb Bio, Inc. · Documents

Track CLYM — free
$9.25 -0.03 (-0.32%)
Market Cap
$545.09M
Shares
58.74M
Volume · Nov 20 264.83K Avg daily vol (3M) 1.37M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $59.85M 10-K filed Mar 5, 2026 Quarterly report FY2026 Q3 Net loss $14.57M 10-Q filed Nov 5, 2026 Latest results Trial dosing began; remission data reported 8-K filed Nov 5, 2026
2026
Nov 9
Investor event
Cash runway reaches second half of 2028, including pivotal spend

Climb Bio said its cash runway reaches into the second half of 2028, inclusive of all pivotal startup and CMC spend, as it moves toward pivotal studies. For its BUDO program, enrollment in the 600 dose is complete and the 1,000 dose is enrolling.

2 source passages
So right now, our cash runway gets us into the second half of 2028, but that is also inclusive of all the Pivotal startup and CMC spend. So we have completed enrollment in the 600. We're enrolling in the 1,000. Open the document at this passage
Nov 9
Investor event
Clinical programs advance toward phase three

Climb Bio is advancing BUDO toward a phase three PMN study and its APRIL antibody toward phase three IgA nephropathy development, with cash runway into the second half of 2028.

8 source passages
Climb Bio, for those of you who don't know us, we're a public biotech company focused on developing B-cell targeted therapies for INI indications. When we in-licensed BUDO, there was a study that had been started but hadn't been finished by the prior sponsor. PMN is a rare renal disease mediated by autoantibodies. It was a single phase three study. The first asset is a CD19-targeted monoclonal antibody, and then the second asset targets APRIL, which is a circulating cytokine that's an important mediator of B-cell differentiation and maintenance. we want to take it into a cohort of patients with IgA nephropathy. we're excited to advance it to phase three. So right now, our cash runway gets us into the second half of 2028, but that is also inclusive of all the Pivotal startup and CMC spend. Open the document at this passage
Nov 5
Registration statement S-3ASR
Launches automatic shelf for future securities

Climb Bio, Inc. launched an automatic shelf registration allowing future sales of multiple securities, with offering amounts and terms to be determined.

Read from the first part of this long document
3 source passages
CLIMB BIO, INC. This prospectus is part of an automatic shelf registration statement on Form S-3ASR that we filed with the Securities and Exchange Commission, which we refer to as the “SEC,” as a “well-known seasoned issuer,” as defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”), utilizing a “shelf” registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Budoprutug shows dose-dependent B-cell depletion

Budoprutug produced deeper peripheral B-cell depletion at 600 mg, with mean suppression of 98% at Week 4. Climb Bio, Inc. reported $227.6 million in cash and marketable securities on September 30, 2026, funding operations into the second half of 2028.

Net loss $14.57M Diluted EPS -$0.18
Read from the MD&A section
2 source passages
Initial data from the ongoing 600 mg cohort suggest greater drug exposure and deeper peripheral B-cell depletion compared with 200 mg, with mean peripheral CD20+ B-cell suppression at Week 4 of 98% at 600 mg compared with 74% at 200 mg. Cash, cash equivalents, and marketable securities were $227.6 million as of September 30, 2026. Based on our current operating plan, we expect this balance to fund operations into the second half of 2028. Open the document at this passage
Nov 5
Current report 8-K
Trial dosing began; remission data reported

Climb Bio began dosing in the NAVIGATE-2 Phase 2 trial for IgAN. Budoprutug’s 200 mg cohort demonstrated B-cell depletion, PLA2R antibody reductions, and immunologic remission at Week 12.

Financial results, Regulation FD disclosure Read from the first part of this long document
3 source passages
Climb Bio, Inc. Initiated dosing in NAVIGATE-2 Phase 2 trial in IgA nephropathy (IgAN); enrollment ongoing. At Week 12, the 200 mg cohort demonstrated B-cell depletion, reductions in PLA2R antibody levels, and immunologic remission. Open the document at this passage
Oct 26
Current report 8-K Events of Oct 24
Budoprutug reduces PLA2R antibodies 70% at Week 12 in pMN

Climb Bio reported initial PrisMN Phase 2 data for budoprutug in primary membranous nephropathy, with a mean PLA2R antibody reduction of 70% at Week 12 in the 200 mg cohort. The 600 mg cohort showed mean peripheral CD20+ B-cell suppression of 98% at Week 4, versus 74% at 200 mg. The drug was generally well tolerated, and additional Phase 2 data are anticipated in 2027.

Regulation FD disclosure, Other events Read from the first part of this long document
4 source passages
The mean PLA2R antibody reduction was 70% at Week 12, and five of 13 patients (38%) achieved immunologic remission. Initial data from the ongoing 600 mg cohort suggest greater drug exposure and deeper peripheral B-cell depletion compared with 200 mg, with mean peripheral CD20+ B-cell suppression at Week 4 of 98% at 600 mg, compared with 74% at 200 mg. Budoprutug has been generally well tolerated in the 200 mg and 600 mg cohorts, with follow-up through Week 12 for 200 mg and through Week 6 for 600 mg. The Company anticipates additional data from the PrisMN Phase 2 trial in 2027. Open the document at this passage
Oct 23
Current report 8-K
CLYM116 data show ~33-day half-life and deep APRIL suppression

Climb Bio and Mabworks reported additional Phase 1 CLYM116/MIL116 data in healthy volunteers. CLYM116 showed an estimated half-life of approximately 33 days, and a single SC injection of 480 mg or higher produced free APRIL suppression of 90% or more through the full 12-week dosing interval. An 800 mg dose produced approximately 70% reduction in Gd-IgA1 at 12 weeks.

Regulation FD disclosure, Other events
4 source passages
issued a press release announcing results for additional Phase 1 data in healthy volunteers for CLYM116/MIL116 CLYM116 showed an estimated half-life of approximately 33 days based on the 800 mg dose and 320 mg multiple-ascending dose (“MAD”) cohort. In the expanded dataset, a single subcutaneous (“SC”) injection of 480 mg or higher produced free APRIL suppression of 90% or more through the full 12-week dosing interval a single SC injection of 800 mg, the selected loading dose for the NAVIGATE-2 Phase 2 trial, produced reductions of approximately 70% in Gd-IgA1 and approximately 60% in IgA at 12 weeks. Open the document at this passage
Aug 14
Current report 8-K Events of Aug 13
Other events AI summary on its way
Jun 11
Current report 8-K
Other events AI summary on its way
Jun 5
Current report 8-K
Other events AI summary on its way
Apr 24
Proxy statement DEF 14A Meeting Jun 5, 2026
Proxy statement AI summary on its way
Apr 10
Proxy statement PRE 14A Meeting Jun 5, 2026
Proxy statement AI summary on its way
Mar 5
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $59.85M Diluted EPS -$0.88
2025
Showing 1–50 of 126 documents
Key facts CIK 1768446 CUSIP 28658R106 13F (30d) 131 filings 123 filers Visit website Investor relations